Novo Nordisk Real-World Data: Ozempic 2mg Shows Lower Cardiovascular Risk Than Eli Lilly's Mounjaro
nashnova research
A US real-world study covering more than 630,000 patients found that upgrading from semaglutide 1mg to Ozempic 2mg carried a 6% lower risk of major cardiovascular events than switching to Eli Lilly's Mounjaro — the first statistically significant head-to-head cardiovascular comparison between the two GLP-1 giants.
What exactly did this study compare?
The study, called COMPETE SWITCH CV, tracked two upgrade paths for the same patient population: stay within the Novo Nordisk system and raise the semaglutide dose from 1mg to 2mg, or switch to tirzepatide (Mounjaro's active ingredient).
The primary endpoint was MACE — major adverse cardiovascular events, covering heart attack, stroke, and cardiovascular death. The Ozempic 2mg group showed a 6% lower risk, and the difference was statistically significant.
This means → in this real-world dataset, "stay on semaglutide and dose up" delivered better cardiovascular outcomes than "switch to the competitor."
Where did the data come from — and how solid is it?
The data source is a large US health-insurance claims database spanning January 2018 to September 2025, covering over 630,000 adults with type 2 diabetes on GLP-1 therapy, with roughly two years of follow-up.
Sample breakdown: about 67% of patients stayed on semaglutide 1mg, about 29% upgraded to 2mg, and only about 4% switched to tirzepatide.
In plain terms = this is a "look back through medical records" analysis, not a gold-standard trial where patients are randomly assigned from the start — it sits below a randomized controlled trial (RCT) on the evidence ladder, and the findings need stricter trials to confirm.
What are the obvious gaps in the study design?
The study did not include safety endpoints — it compared cardiovascular event rates only, with no reporting on side-effect differences between the two paths.
Patients who switched to tirzepatide made up just 4% of the sample; the comparator group is far smaller than the semaglutide group, which may limit statistical power.
This means → the 6% gap is statistically significant, but it is not yet a settled conclusion on the evidence chain — the market is waiting for a head-to-head randomized trial.
Why release this data right now?
Novo Nordisk and Eli Lilly are in full competition across the GLP-1 market, and both are aggressively expanding their products' cardiovascular indications.
This reflects a deliberate timing choice — releasing the data ahead of an oral presentation at the European Association for the Study of Diabetes annual meeting to capture physician and market attention.
In plain terms = real-world data is the fastest card Novo Nordisk can play right now; whether this 6% advantage holds up in a randomized trial is the variable that will actually shape the competitive landscape.
市场有风险，内容仅供研究参考，不构成投资建议。